1,091 results on '"Sternberg C"'
Search Results
2. Functional outcome and return to sports after the arthroscopic latarjet procedure in young and physically active patients
3. Randomized Trial of Five or Two MRI-guided Adaptive Radiotherapy Treatments for Prostate Cancer (FORT)
4. Dosierung, Sicherheit und Pharmakokinetik der Kombinationstherapie mit Darolutamid (DARO), Androgendeprivationstherapie (ADT) und Docetaxel (DOC) bei Patienten mit metastasiertem hormonsensitivem Prostatakarzinom (mHSPC) in der ARASENS Studie
5. Effizienz und Sicherheit von Darolutamid (DARO) in Kombination mit Androgendeprivationstherapie (ADT) und Docetaxel (DOC) nach Krankheitsvolumen und -risiko in der Phase 3 ARASENS Studie
6. Lebensqualität und Patienten-relevante Endpunkte unter Darolutamid-Therapie in der Phase-3-Studie ARASENS
7. The architecture of political representation. A historiographical review
8. Second-line treatment for metastatic clear cell renal cell cancer: experts’ consensus algorithms
9. Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer
10. 1390P Circulating tumor DNA (ctDNA) and prognosis with PSMA-targeted radionuclide therapy (TRT)
11. 1360MO Quality of life and patient-relevant endpoints with darolutamide in the phase III ARASENS study
12. LBA74 Genomic biomarkers in peripheral blood (PB) from patients (pts) enrolled in the JAVELIN Bladder 100 trial of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC)
13. 1746P Disease-free survival (DFS) and distant metastasis-free survival (DMFS) as surrogates for overall survival (OS) in adjuvant treatment of muscle-invasive bladder cancer (MIBC)
14. Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)
15. A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy
16. Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer
17. Chemotherapy Before Definitive Treatment for Locally Advanced Bladder Cancer
18. B19 - Patient (pt) characteristics and treatment patterns in the radium (Ra)-223 REASSURE observational study
19. Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy
20. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL
21. The use of biosimilar medicines in oncology--position statement of the Brazilian Society of Clinical Oncology (SBOC)
22. Radiotherapy modulates expression of EGFR, ERCC1 and p53 in cervical cancer
23. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
24. The Skull of Leidyosuchus canadensis Lambe
25. The Systematic Position of Trachodon
26. Pachycephalosauridae Proposed for Dome-Headed Dinosaurs, Stegoceras lambei, n. sp., Described
27. Thescelosaurus edmontonensis, n. sp., and Classification of the Hypsilophodontidae
28. Ceratopsidae from Alberta
29. Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study
30. Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multi-center international trial.
31. Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study.
32. Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study
33. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial†
34. Erratum: Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC) (Annals of Oncology (2018) 29(2) (361–369), (S0923753419350392), (10.1093/annonc/mdx692))
35. P12.02 Implementation of a Timeliness-of-care Pathway System for Lung Cancer Patients in a Private Outpatient Oncology Service.
36. Re: A Randomised, Double-Blind Phase III Study of Pazopanib in Patients with Advanced and/or Metastatic Renal Cell Carcinoma: Final Overall Survival Results and Safety Update
37. Prognostic effect of systemic immune-inflammation index (SII) in 987 patients with advanced/metastatic urinary tract carcinoma (mUTC) treated with atezolizumab in the real-world global SAUL study
38. Prognostic effect of systemic immune-inflammation index (SII) in 987 patients with advanced/metastatic urinary tract carcinoma (mUTC) treated with atezolizumab in the real-world global SAUL study
39. Neutrophil-lymphocyte ratio (NLR) as a prognostic and predictive biomarker in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (CBZ) vs abiraterone or enzalutamide in the CARD study
40. Prognostic factors related to post-platinum atezolizumab for relapsed metastatic urothelial cancer (mUC) from the SAUL study
41. Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy†
42. Novel hormonal therapy for castration-resistant prostate cancer
43. A New Fossil Crocodile from Saskatchewan
44. Two New Theropod Dinosaurs from the Belly River Formation of Alberta
45. New Records of Mastodons and Mammoths in Canada
46. Horned Dinosaur Group in the National Museum of Canada
47. Notes on the Lance Formation of Southern Saskatchewan
48. A Popular Description of Dinosaurs
49. Neue Dynastiden-Arten
50. Pigmentation Mosaicism in Intersexes of Drosophila
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.